Table 4 Net effectiveness based on WHO recommended criteria. Optimal effectiveness: KD60 ≥ 95% or mortality ≥ 80%, minimal effectiveness: KD60 ≥ 75% or mortality ≥ 50%.
A | Proportion of nets with optimal effectiveness at different times of follow-up | |||||
|---|---|---|---|---|---|---|
Type of net | Baseline (n) % 95% CI | 6 Months (n) % 95% CI | 12 Months (n) % 95% CI | 18/20 Months (n) % 95% CI | 24/27 Months (n) % 95% CI | 36/39 Months (n) % 95% CI |
PermaNet 1st generation | (10) 100 69.2 – 100 | (40) 37.5 22.7 – 54.2 | (40) 42.5 27.0 – 59.1 | (40) 15.0 5.7 – 29.8 | (40) 45.0 29.3 – 61.5 | (38) 10.5 2.9 – 24.8 |
PermaNet 2nd generation | (10) 100 69.2 – 100 | (40) 100 91.2 – 100 | (40) 97.5 86.8 – 99.9 | (40) 97.5 86.8 – 99.9 | (38) 71.0 54.1 – 84.6 | (40) 90.0 76.3 – 97.2 |
Conventional net | (10) 100 69.2 – 100 | (40) 7.5 1.6 – 20.4 | Not done | Not done | Not done | Not done |
Conventional net retreated | (13) 100 75.3 – 100 | (34) 61.8 43.6 – 77.6 | (11) 45.5 16.8 – 76.6 | Not done | Not done | Not done |
B | Proportion of nets with minimal effectiveness at different times of follow-up | |||||
Type of net | Baseline (n) % 95% CI | 6 Months (n) % 95% CI | 12 Months (n) % 95% CI | 18/20 Months (n) % 95% CI | 24/27 Months (n) % 95% CI | 36/39 Months (n) % 95% CI |
PermaNet 1st generation | (10) 100 69.2 – 100 | (40) 70.0 53.5 – 83.4 | (40) 60.0 43.3 – 75.1 | (40) 30.0 16.6 – 46.5 | (40) 65.0 48.3 – 79.4 | (38) 18.4 7.7 – 34.3 |
PermaNet 2nd generation | (10) 100 69.2 – 100 | (40) 100 91.2 – 100 | (40) 100 91.2 – 100 | (40) 100 91.2 – 100 | (38) 92.1 78.6 – 98.3 | (40) 100 91.2 – 100 |
Conventional net | (10) 100 69.2 – 100 | (40) 25.0 12.7 – 41.2 | Not done | Not done | Not done | Not done |
Conventional net retreated | (13) 100 75.3 – 100 | (34) 73.5 55.6 -87.1 | (11) 72.7 39.0 – 99.9 | Not done | Not done | Not done |